Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase II trial of avastin (A) [bevacizumab] or avastin and erlotinib (AE) as first line consolidation chemotherapy after carboplatin, paclitaxel and avastin (CTA) induction therapy for newly diagnosed advanced ovarian, fallopian tube and primary peritoneal cancer and papillary serous mullerian tumours

Next Previous
Trial Profile

A randomized phase II trial of avastin (A) [bevacizumab] or avastin and erlotinib (AE) as first line consolidation chemotherapy after carboplatin, paclitaxel and avastin (CTA) induction therapy for newly diagnosed advanced ovarian, fallopian tube and primary peritoneal cancer and papillary serous mullerian tumours

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Carboplatin; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 02 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 26 Aug 2013 Planned end date changed from 1 Jan 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
  • 03 Dec 2012 Planned End Date changed from 1 Aug 2010 to 1 Jan 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top